Tiger Brokers

Xilio Therapeutics Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million

Reuters
Yesterday
<a href="https://laohu8.com/S/XLO">Xilio Therapeutics</a> Q4 license revenue rose 100% to USD 14 million, net income was USD 10 million
  • Xilio published a press release with fourth-quarter and full-year 2025 financial results alongside pipeline and business updates.
  • Q4 collaboration and license revenue rose more than sevenfold to USD 13.7 million, driven by revenue recognized under the AbbVie collaboration and higher revenue under the Gilead license tied to a development milestone.
  • Q4 R&D expense more than doubled to USD 18.1 million, reflecting IND-enabling manufacturing and preclinical work for XTX501, higher efarindodekin alfa clinical development activity, and increased masked T cell engager program costs.
  • Q4 net income was USD 10.4 million, compared with a net loss in the prior-year quarter.
  • Cash and cash equivalents totaled USD 137.5 million at year-end, and Xilio said its cash runway is expected to extend through the end of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230730PRIMZONEFULLFEED9676136) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10